In this episode, we’re joined by Dr. Piraye Yurttas Beim, founder and CEO of Celmatix, a women’s health biotech company. She discusses the funding the company recently received through the Sprint for Women's Health program.
23andMe and Celmatix are combining forces to understand the genomic underpinnings of infertility.
Hear executives from Quantum Health, Surescripts, EY, Clinical Architecture and Personify Health share their views on digital transformation in healthcare.
New York startup Celmatix just raised $5.5 million for its predictive software that determines a woman's likelihood of infertility based on her genomics.